01.23.14
Syndax Announces Appointment of Richard P. Shea as Independent Director and Chair of the Audit Committee
Read More
11.01.13
Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer
Read More
09.11.13
Syndax’s Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer
Read More
09.04.13
Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries
Read More
08.27.13
Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Read More
05.14.13
Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
Read More
05.09.13
Syndax Pharmaceuticals to Commercialize First-in-Class Lung Cancer Treatment Developed at the University of Colorado
Read More
05.29.12
Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
Read More
05.16.12
Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Directors
Read More
04.30.12
Syndax Pharmaceuticals Announces Publication of Entinostat Phase 2 Clinical Trial Data in Journal of Clinical Oncology
Read More
04.18.12
Syndax Pharmaceuticals Appoints Arlene Morris as CEO
Read More
04.09.12
Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
Read More